JAHA:PCSK9抑制剂可改善HIV携带者冠脉健康

2020-07-20 MedSci原创 MedSci原创

PCSK9(前蛋白转化酶枯草杆菌素9型)因其在胆固醇代谢中的重要作用而被熟知。PCSK9水平的升高可增加心血管疾病风险,PCSK9抑制剂(PCSK9i)可以降低冠心病患者的心血管事件发生率。PCSK9

PCSK9(前蛋白转化酶枯草杆菌素9型)因其在胆固醇代谢中的重要作用而被熟知。PCSK9水平的升高可增加血管疾病风险,PCSK9抑制剂(PCSK9i)可以降低冠心病患者的心血管事件发生率。PCSK9水平在HIV感染者(PLWH)和血脂异常者中也升高。因为PLWH中PCSK9的增加与冠状动脉内皮功能受损有关,本研究的目的旨在验证PCSK9i可以改善无冠心病血脂异常和PLWH伴高低密度脂蛋白胆固醇水平患者的冠状动脉内皮功能受损的假设。

本单中心研究纳入分析了19名PLWH患者和11名高血脂患者,PCSK9i治疗前,两组患者在握力训练中冠状动脉血管扩张减少或没有增加(正常反应)。经过6周PCSK9i治疗,PLWH组和血脂异常组从静息到握力运动的横截面积变化率分别为+5.6±5.5%和+4.5±3.1%,两者均P<0.01。另外,两组的冠状动脉血流量也有显着改善。

研究结果显示,PCSK9抑制剂可以改善HIV感染者和血脂异常患者的冠脉健康。

原始出处:

Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia.JAHA.2020 July.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786876, encodeId=10141e868762f, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 09 21:10:31 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777294, encodeId=d8ee1e77294a2, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Nov 06 00:10:31 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852439, encodeId=08591852439ac, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 03 14:10:31 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685639, encodeId=d9951685639e8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Jan 19 08:10:31 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004936, encodeId=2be5200493607, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jul 27 14:10:31 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803872, encodeId=91f58038e2f2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Wed Jul 22 11:04:50 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268294, encodeId=acab126829491, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jul 22 01:10:31 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803624, encodeId=b489803624ba, content=这有点吓人啦(๑ó﹏ò๑), beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/e0fbd563d9054278997cb567f3351d90/db37f938d1ea4a96a7e324c062c9461b.jpg, createdBy=3d615392683, createdName=ms7000000593056838, createdTime=Tue Jul 21 07:28:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803523, encodeId=b8328035238f, content=哇,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=ms5000001130736387, createdTime=Mon Jul 20 20:04:07 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803512, encodeId=9674803512e1, content=降脂保护作用,可以减少抗艾治疗的副作用<a href='/topic/show?id=a48786e89c1' target=_blank style='color:#2F92EE;'>#艾滋病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86789, encryptionId=a48786e89c1, topicName=艾滋病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 20 18:27:26 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786876, encodeId=10141e868762f, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 09 21:10:31 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777294, encodeId=d8ee1e77294a2, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Nov 06 00:10:31 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852439, encodeId=08591852439ac, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 03 14:10:31 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685639, encodeId=d9951685639e8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Jan 19 08:10:31 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004936, encodeId=2be5200493607, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jul 27 14:10:31 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803872, encodeId=91f58038e2f2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Wed Jul 22 11:04:50 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268294, encodeId=acab126829491, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jul 22 01:10:31 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803624, encodeId=b489803624ba, content=这有点吓人啦(๑ó﹏ò๑), beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/e0fbd563d9054278997cb567f3351d90/db37f938d1ea4a96a7e324c062c9461b.jpg, createdBy=3d615392683, createdName=ms7000000593056838, createdTime=Tue Jul 21 07:28:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803523, encodeId=b8328035238f, content=哇,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=ms5000001130736387, createdTime=Mon Jul 20 20:04:07 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803512, encodeId=9674803512e1, content=降脂保护作用,可以减少抗艾治疗的副作用<a href='/topic/show?id=a48786e89c1' target=_blank style='color:#2F92EE;'>#艾滋病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86789, encryptionId=a48786e89c1, topicName=艾滋病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 20 18:27:26 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-11-06 FukaiBao
  3. [GetPortalCommentsPageByObjectIdResponse(id=1786876, encodeId=10141e868762f, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 09 21:10:31 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777294, encodeId=d8ee1e77294a2, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Nov 06 00:10:31 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852439, encodeId=08591852439ac, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 03 14:10:31 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685639, encodeId=d9951685639e8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Jan 19 08:10:31 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004936, encodeId=2be5200493607, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jul 27 14:10:31 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803872, encodeId=91f58038e2f2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Wed Jul 22 11:04:50 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268294, encodeId=acab126829491, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jul 22 01:10:31 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803624, encodeId=b489803624ba, content=这有点吓人啦(๑ó﹏ò๑), beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/e0fbd563d9054278997cb567f3351d90/db37f938d1ea4a96a7e324c062c9461b.jpg, createdBy=3d615392683, createdName=ms7000000593056838, createdTime=Tue Jul 21 07:28:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803523, encodeId=b8328035238f, content=哇,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=ms5000001130736387, createdTime=Mon Jul 20 20:04:07 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803512, encodeId=9674803512e1, content=降脂保护作用,可以减少抗艾治疗的副作用<a href='/topic/show?id=a48786e89c1' target=_blank style='color:#2F92EE;'>#艾滋病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86789, encryptionId=a48786e89c1, topicName=艾滋病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 20 18:27:26 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-08-03 jklm09
  4. [GetPortalCommentsPageByObjectIdResponse(id=1786876, encodeId=10141e868762f, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 09 21:10:31 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777294, encodeId=d8ee1e77294a2, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Nov 06 00:10:31 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852439, encodeId=08591852439ac, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 03 14:10:31 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685639, encodeId=d9951685639e8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Jan 19 08:10:31 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004936, encodeId=2be5200493607, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jul 27 14:10:31 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803872, encodeId=91f58038e2f2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Wed Jul 22 11:04:50 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268294, encodeId=acab126829491, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jul 22 01:10:31 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803624, encodeId=b489803624ba, content=这有点吓人啦(๑ó﹏ò๑), beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/e0fbd563d9054278997cb567f3351d90/db37f938d1ea4a96a7e324c062c9461b.jpg, createdBy=3d615392683, createdName=ms7000000593056838, createdTime=Tue Jul 21 07:28:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803523, encodeId=b8328035238f, content=哇,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=ms5000001130736387, createdTime=Mon Jul 20 20:04:07 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803512, encodeId=9674803512e1, content=降脂保护作用,可以减少抗艾治疗的副作用<a href='/topic/show?id=a48786e89c1' target=_blank style='color:#2F92EE;'>#艾滋病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86789, encryptionId=a48786e89c1, topicName=艾滋病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 20 18:27:26 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2021-01-19 Tamikia
  5. [GetPortalCommentsPageByObjectIdResponse(id=1786876, encodeId=10141e868762f, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 09 21:10:31 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777294, encodeId=d8ee1e77294a2, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Nov 06 00:10:31 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852439, encodeId=08591852439ac, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 03 14:10:31 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685639, encodeId=d9951685639e8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Jan 19 08:10:31 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004936, encodeId=2be5200493607, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jul 27 14:10:31 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803872, encodeId=91f58038e2f2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Wed Jul 22 11:04:50 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268294, encodeId=acab126829491, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jul 22 01:10:31 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803624, encodeId=b489803624ba, content=这有点吓人啦(๑ó﹏ò๑), beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/e0fbd563d9054278997cb567f3351d90/db37f938d1ea4a96a7e324c062c9461b.jpg, createdBy=3d615392683, createdName=ms7000000593056838, createdTime=Tue Jul 21 07:28:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803523, encodeId=b8328035238f, content=哇,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=ms5000001130736387, createdTime=Mon Jul 20 20:04:07 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803512, encodeId=9674803512e1, content=降脂保护作用,可以减少抗艾治疗的副作用<a href='/topic/show?id=a48786e89c1' target=_blank style='color:#2F92EE;'>#艾滋病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86789, encryptionId=a48786e89c1, topicName=艾滋病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 20 18:27:26 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-07-27 qblt
  6. [GetPortalCommentsPageByObjectIdResponse(id=1786876, encodeId=10141e868762f, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 09 21:10:31 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777294, encodeId=d8ee1e77294a2, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Nov 06 00:10:31 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852439, encodeId=08591852439ac, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 03 14:10:31 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685639, encodeId=d9951685639e8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Jan 19 08:10:31 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004936, encodeId=2be5200493607, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jul 27 14:10:31 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803872, encodeId=91f58038e2f2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Wed Jul 22 11:04:50 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268294, encodeId=acab126829491, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jul 22 01:10:31 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803624, encodeId=b489803624ba, content=这有点吓人啦(๑ó﹏ò๑), beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/e0fbd563d9054278997cb567f3351d90/db37f938d1ea4a96a7e324c062c9461b.jpg, createdBy=3d615392683, createdName=ms7000000593056838, createdTime=Tue Jul 21 07:28:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803523, encodeId=b8328035238f, content=哇,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=ms5000001130736387, createdTime=Mon Jul 20 20:04:07 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803512, encodeId=9674803512e1, content=降脂保护作用,可以减少抗艾治疗的副作用<a href='/topic/show?id=a48786e89c1' target=_blank style='color:#2F92EE;'>#艾滋病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86789, encryptionId=a48786e89c1, topicName=艾滋病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 20 18:27:26 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-07-22 ms7000001773953003

    谢谢

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1786876, encodeId=10141e868762f, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 09 21:10:31 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777294, encodeId=d8ee1e77294a2, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Nov 06 00:10:31 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852439, encodeId=08591852439ac, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 03 14:10:31 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685639, encodeId=d9951685639e8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Jan 19 08:10:31 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004936, encodeId=2be5200493607, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jul 27 14:10:31 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803872, encodeId=91f58038e2f2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Wed Jul 22 11:04:50 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268294, encodeId=acab126829491, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jul 22 01:10:31 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803624, encodeId=b489803624ba, content=这有点吓人啦(๑ó﹏ò๑), beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/e0fbd563d9054278997cb567f3351d90/db37f938d1ea4a96a7e324c062c9461b.jpg, createdBy=3d615392683, createdName=ms7000000593056838, createdTime=Tue Jul 21 07:28:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803523, encodeId=b8328035238f, content=哇,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=ms5000001130736387, createdTime=Mon Jul 20 20:04:07 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803512, encodeId=9674803512e1, content=降脂保护作用,可以减少抗艾治疗的副作用<a href='/topic/show?id=a48786e89c1' target=_blank style='color:#2F92EE;'>#艾滋病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86789, encryptionId=a48786e89c1, topicName=艾滋病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 20 18:27:26 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-07-22 zhaohui6731
  8. [GetPortalCommentsPageByObjectIdResponse(id=1786876, encodeId=10141e868762f, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 09 21:10:31 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777294, encodeId=d8ee1e77294a2, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Nov 06 00:10:31 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852439, encodeId=08591852439ac, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 03 14:10:31 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685639, encodeId=d9951685639e8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Jan 19 08:10:31 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004936, encodeId=2be5200493607, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jul 27 14:10:31 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803872, encodeId=91f58038e2f2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Wed Jul 22 11:04:50 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268294, encodeId=acab126829491, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jul 22 01:10:31 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803624, encodeId=b489803624ba, content=这有点吓人啦(๑ó﹏ò๑), beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/e0fbd563d9054278997cb567f3351d90/db37f938d1ea4a96a7e324c062c9461b.jpg, createdBy=3d615392683, createdName=ms7000000593056838, createdTime=Tue Jul 21 07:28:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803523, encodeId=b8328035238f, content=哇,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=ms5000001130736387, createdTime=Mon Jul 20 20:04:07 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803512, encodeId=9674803512e1, content=降脂保护作用,可以减少抗艾治疗的副作用<a href='/topic/show?id=a48786e89c1' target=_blank style='color:#2F92EE;'>#艾滋病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86789, encryptionId=a48786e89c1, topicName=艾滋病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 20 18:27:26 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-07-21 ms7000000593056838

    这有点吓人啦(๑ó﹏ò๑)

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1786876, encodeId=10141e868762f, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 09 21:10:31 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777294, encodeId=d8ee1e77294a2, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Nov 06 00:10:31 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852439, encodeId=08591852439ac, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 03 14:10:31 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685639, encodeId=d9951685639e8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Jan 19 08:10:31 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004936, encodeId=2be5200493607, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jul 27 14:10:31 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803872, encodeId=91f58038e2f2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Wed Jul 22 11:04:50 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268294, encodeId=acab126829491, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jul 22 01:10:31 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803624, encodeId=b489803624ba, content=这有点吓人啦(๑ó﹏ò๑), beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/e0fbd563d9054278997cb567f3351d90/db37f938d1ea4a96a7e324c062c9461b.jpg, createdBy=3d615392683, createdName=ms7000000593056838, createdTime=Tue Jul 21 07:28:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803523, encodeId=b8328035238f, content=哇,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=ms5000001130736387, createdTime=Mon Jul 20 20:04:07 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803512, encodeId=9674803512e1, content=降脂保护作用,可以减少抗艾治疗的副作用<a href='/topic/show?id=a48786e89c1' target=_blank style='color:#2F92EE;'>#艾滋病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86789, encryptionId=a48786e89c1, topicName=艾滋病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 20 18:27:26 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-07-20 ms5000001130736387

    哇,学习了

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1786876, encodeId=10141e868762f, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Aug 09 21:10:31 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777294, encodeId=d8ee1e77294a2, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Fri Nov 06 00:10:31 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852439, encodeId=08591852439ac, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 03 14:10:31 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685639, encodeId=d9951685639e8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Tue Jan 19 08:10:31 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004936, encodeId=2be5200493607, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Mon Jul 27 14:10:31 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803872, encodeId=91f58038e2f2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Wed Jul 22 11:04:50 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268294, encodeId=acab126829491, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jul 22 01:10:31 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803624, encodeId=b489803624ba, content=这有点吓人啦(๑ó﹏ò๑), beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200930/e0fbd563d9054278997cb567f3351d90/db37f938d1ea4a96a7e324c062c9461b.jpg, createdBy=3d615392683, createdName=ms7000000593056838, createdTime=Tue Jul 21 07:28:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803523, encodeId=b8328035238f, content=哇,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/956eb01f4b594ee783debae7a44d9096/e569cb8381764328b493c23491d86c27.jpg, createdBy=2cbc5401622, createdName=ms5000001130736387, createdTime=Mon Jul 20 20:04:07 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803512, encodeId=9674803512e1, content=降脂保护作用,可以减少抗艾治疗的副作用<a href='/topic/show?id=a48786e89c1' target=_blank style='color:#2F92EE;'>#艾滋病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86789, encryptionId=a48786e89c1, topicName=艾滋病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 20 18:27:26 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-07-20 lovetcm

    降脂保护作用,可以减少抗艾治疗的副作用#艾滋病#

    0

相关资讯

JAHA:门诊利尿剂强化治疗会增加心衰患者死亡风险

失代偿性心力衰竭(HF)住院后死亡率增加,在此期间利尿剂通常会加重,目前尚不清楚在门诊强化利尿剂治疗心力衰竭后风险是如何影响的。

JAHA:年龄对收缩压与心血管病风险相关性的影响研究

糖尿病患者收缩压(SBP)与心血管疾病(CVD)的关系尚不清楚。本研究旨在探讨SBP与CVD之间的年龄相关性。

JACC:外周动脉疾病患者的他汀药使用情况

外周动脉疾病(PAD)会增加动脉粥样硬化疾病(ASCVD)的发病风险。本研究的目的是比较PAD患者与冠心病(CHD)或脑血管病患者发生ASCVD事件的风险以及他汀类药物的使用情况。

JAHA:冠状病毒疾病的心血管并发症研究

本荟萃分析的目的旨在探讨COVID-19、SARS和MERS患者心血管并发症的患病率。

JACC:RAAS抑制剂不会增加COVID-19风险

冠状病毒病-2019(COVID-19)是由严重急性呼吸综合征冠状病毒-2引起的,冠状病毒2通过血管紧张素转换酶2与肾素-血管紧张素-醛固酮系统(RAAS)结合。这种相互作用被认为是RAAS抑制剂治疗

JACC:COVID-19大流行期间心血管病住院率明显下降

尽管心血管疾病患者面临COVID-19时患严重疾病的风险很高,但这次大流行可能对这些高危患者存在非直接的影响。本研究旨在探讨三级医疗卫生系统中急性心血管疾病住院的纵向趋势。